(772) 276-7242 Mon–Fri 9:00am–4:30pm

Home/Cancers/Myelodysplastic syndromes (MDS)

Myelodysplastic syndromes (MDS)

When the bone marrow needs an expert eye — and a long-term partner.

Myelodysplastic syndromes are conditions in which the bone marrow produces blood cells abnormally, most often discovered through persistently low blood counts in older adults. MDS ranges from indolent forms needing only monitoring and supportive care to higher-risk disease requiring active treatment. Our hematologists manage that full range — with the regular monitoring, transfusions, and modern therapies MDS care requires, all close to home.

How we approach it

Accurate risk stratification

Marrow evaluation and molecular testing establish your risk category — which drives every decision

Supportive care on-site

Growth-factor support and coordination of transfusions, with lab monitoring at every visit

Active treatment when needed

Hypomethylating therapy and other modern options delivered in our infusion center

What the workup looks like

1
Establishing the diagnosis

Persistent count abnormalities lead to marrow evaluation — the definitive test that confirms MDS and reveals its biology.

2
Risk category

Validated scoring tools place your MDS on the risk spectrum, separating watch-and-support from treat-now.

3
Your ongoing plan

Whether monitoring, supportive care, or active therapy, MDS care is continuous — and our team manages it visit to visit.

Common questions

Is MDS cancer?
MDS is classified as a bone marrow cancer, though many forms behave indolently for years. What matters most is your specific risk category — which we’ll establish and explain.
Can MDS turn into leukemia?
Higher-risk MDS can progress to acute leukemia, which is why risk stratification and monitoring matter. Lower-risk MDS often never progresses.
Will I need regular transfusions?
Some patients do, especially over time. We coordinate transfusion support and use treatments that can reduce or eliminate the need.
Is there treatment beyond transfusions?
Yes — growth factors, hypomethylating agents, and other modern therapies, plus transplant referral for the minority of patients where that’s the right path.

This page is general information, not medical advice for your specific situation. Every cancer — and every patient — is different. Bring your questions to your care team.